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Abstract
Background: The most frequent and malignant brain cancer is glioblastoma multiforme (GBM). In gliomas, tumor
progression and poor prognosis are associated with the tumorigenic ability of the cells. U87MG cells (wild-type p53) are
known to be tumorigenic in nude mice, but T98G cells (mutant p53) are not tumorigenic. We investigated the proteomic
profiling of these two cell lines in order to gain new insights into the mechanisms that may be involved in tumorigenesis.
Results: We found 24 differentially expressed proteins between T98G and U87MG cells. Gene Ontology supports the
notion that over-representation of differentially expressed proteins is involved in glycolysis, cell migration and stress
oxidative response. Among those associated with the glycolysis pathway, TPIS and LDHB are up-regulated in U87MG cells.
Measurement of glucose consumption and lactate production suggests that glycolysis is more effective in U87MG cells.
On the other hand, G6PD expression was 3-fold higher in T98G cells and this may indicate a shift to the
pentose-phosphate pathway. Moreover, GRP78 expression was also three-fold higher in T98G than in U87MG cells. Under
thapsigargin treatment both cell lines showed increased GRP78 expression and the effect of this agent was inversely
correlated to cell migration. Quantitative RT-PCR and immunohistochemistry of GRP78 in patient samples indicated a
higher level of expression of GRP78 in grade IV tumors compared to grade I and non-neoplastic tissues, respectively.
Conclusions: Taken together, these results suggest an important role of proteins involved in key functions such as
glycolysis and cell migration that may explain the difference in tumorigenic ability between these two glioma cell lines
and that may be extrapolated to the differential aggressiveness of glioma tumors.
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Background
Gliomas are responsible for more than 60% of all pri-
mary brain tumors. Glioblastoma multiforme – GBM, a
grade IV tumor (WHO), is one of the most frequent and
malignant gliomas [1]. GBM is an aggressive, highly in-
vasive tumor that presents resistance to chemo- and
radiotherapy, resulting in a very poor prognosis [2].
Clinical studies have shown improved survival when a
combination of radiation and temozolomide chemothe-
rapy is used, but median survival for GBM patients is
still about 15 months [3].
U87MG and T98G are malignant glioma cell lines
commonly used in functional studies to better under-
stand the biological processes involved in tumor pro-
gression, to test drug therapy, or to search for genetic
mutations. U87MG is hypo diploid [4] while T98G is a
hyperpentaploid cell line [5], a fact that indicates marked
changes in their genomes. Moreover, these two cell lines
present another major difference: while U87MG cells
carry wild-type p53 and are known to be tumorigenic in
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nude mice [6], T98G cells, harboring the mutant p53,
are not tumorigenic. Consequently, p53 mutation alone
is inferred not to be sufficient to induce tumorigenesis
in nude mice [7]. Nevertheless, the presence of func-
tional wild-type p53 or mutant p53 is taken into account
for the genetic sub-classification of GBM as primary or
secondary GBM [8,9].
Tumorigenesis is a complex multistep process that
involves self-sufficiency in growth signals, insensitivity to
growth inhibitory signals, evasion of apoptosis, limitless
replicative potential, sustained angiogenesis, tissue inva-
sion, metastasis and two emerging hallmarks recently,
added to the list: reprogramming of energy of metabo-
lism and evasion of immune destruction [10]. Invasive
and metastatic stages are responsible for most of the
mortality of patients with cancer. Tumorigenic ability
has also been associated with tumor progression and a
poor prognosis in gliomas [11]. Currently, it is unknown
which proteins confer the tumorigenic potential
observed in U87MG cells. Here we investigated the
proteomic profile of U87MG and T98G cell lines and its
correlation to proliferation and migration to gain new
insights into the mechanisms involved in tumorigenesis.
Results
Proteomics analysis: two-dimensional gel electrophoresis
U87MG cells (wild-type p53) are known to be tumori-
genic in nude mice, but T98G cells (mutant p53) are not
tumorigenic. With this in mind, protein extracts of
U87MG and T98G cell lines were compared by 2D gel
electrophoresis. Analysis of 2DE colloidal Coomassie
blue-stained gels detected 386 (SD± 14) protein spots in
T98G cells and 376 (SD± 35) protein spots in U87MG
cells, with molecular masses ranging from 10 to 97 kDa.
These similarities in number of protein spots in U87MG
and T98G cells suggest that these two cell lines share a
common proteome. Representative 2DE gel images from
six replicates are shown in Figure 1A. Differentially
expressed proteins are labeled in Figure 1B and their
identification by mass spectrometry is reported in
Table 1. The percentage of spot volumes (% spot vol)
was used to measure the protein abundance based on
the percent volume of each spot in relation to the sum
of all spots detected in the gel. The reproducibility of
the gels was determined on the basis of the number of
spots that coincided in triplicate gels of two independent
experiments. Differential protein abundance was iden-
tified when the difference in percent volume of each
spot ratio between samples was statistically significant
(p < 0.05, Anova).
Fourteen proteins were increased and 10 decreased in
abundance in U87MG cells compared to T98G cells.
The differentially expressed proteins were classified
according to functional gene ontology (Additional file 1),
which showed an over-representation of proteins
involved in primary metabolic processes, especially gly-
colysis, pentose-phosphate shunt, and protein folding.
Among the proteins with increased expression in
U87MG cells were Annexin A1, Stathmin, 14-3-3E pro-
tein, and some enzymes involved in glycolysis, namely
TPIS and LDHB. It is also worth to highlight GRP78,
involved in protein folding, and G6PD, the first en-
zyme in the pentose phosphate pathway, which showed
3-fold increased expression in T98G cells compared to
U87MG cells.
Proliferation, migration, glucose consumption and lactate
production of T98G and U87MG cells
Because T98G and U87MG cells differ in their tumori-
genic capacity, we looked for differences in their proli-
ferative potential, migration rates, glucose consumption
and lactate production. To investigate their proliferation
rates, cells were counted in a Neubauer chamber every
24 h. Although in the first 72 h after plating the two cell
lines presented similar proliferation rates (Figure 2A),
after this period U87MG cells presented a 2-fold higher
growth rate compared to T98G cells. However, deter-
mination of doubling time between the two cell lines
showed very similar results, i.e., 29.2 h for U87MG and
29.9 h for T98G.
In order to further investigate whether the U87MG cell
line presented a different cell migration potential com-
pared to T98G, a migration assay was performed by the
transwell system using 2.5× 104 cells/mL (500 μL/well) of
each cell line during the first 18 h after plate seeding. As
shown in Figure 2B, the migration rate of U87MG cells
was higher than that of T98G cells (3100± 513 against
260± 30, p < 0.0001). This result suggests that the tumori-
genic ability of U87MG cells may be due to their late
higher proliferation and migration rates. We tested
whether cellular stress was involved in this marked cell
migration difference and submitted both cell lines to an
inducer of endoplasmic reticulum (ER) stress by exposing
them to 1 μM thapsigargin (an endogenous calcium re-
leaser), which is known to induce ER stress and to cause
an unfolded protein response (UPR) corresponding to the
increased expression of GRP78 detected by Western blot-
ting. Accordingly, both cell lines presented a significant
decrease of cell migration (Figure 2B) which was inversely
correlated to ER stress and to a concomitant increase of
GRP78 expression (Figure 2C). To extrapolate this result
to human astrocytoma tumors, we probed GRP78 expres-
sion by qRT-PCR and immunohistochemistry in grade IV
astrocytomas (n= 4) and compared them to grade I
tumors (n= 4) and to non-neoplastic tissue (n= 4). Quan-
titative RT-PCR showed an increased level of GRP78
mRNA in grade IV astrocytomas (Figure 3). Immunohisto-
chemistry also demonstrated an increased expression of
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GRP78 at the protein level in grade IV tumors (Figure 4).
GRP78 showed a scattered pattern in grade IV astrocyto-
mas by both methods, as opposed to a grouped pattern in
grade I tumors and in non-neoplastic tissue.
Since we found an alteration in the expression of se-
veral glycolytic enzymes between these two cell lines, we
evaluated glucose consumption and lactate production
in six replicate samples for each time and during 24 and
48 h cell growth under normoxic conditions. Glucose
quantification indicated no significant difference within
24 h, but U87MG cells tended to consume more glucose
at 48 h than T98G cells, expressed as μg glucose/cell
(Figure 5A, 24 h, p = 0.621 and 48 h, p = 0.0645, Stu-
dent’s t test). However, there was a higher production of
lactate in U87MG cells compared to T98G cells,
expressed as μg/cell (Figure 5B, 24 h, p = 0.001 and 48 h
p = 0.0005, Student's t test). It is noteworthy that, as
shown in Figure 2A, cell proliferation differed only after
72 h of culture and the doubling time was very similar
for both cell lines under normoxic conditions. Our hy-
pothesis is that U87MG cells can use glucose more effi-
ciently than T98G cells due to a moderate consumption
of glucose and a larger production of lactate during cell
culture under similar conditions. These results allow us
to speculate that U87MG cells may have a greater ability
to withstand the initial conditions of hypoxia during
tumor formation than T98G cells.
Discussion
The major difference between these human glioblastoma
cell lines, U87MG and T98G, is the tumorigenic poten-
tial of U87MG cells in nude mice [6,7]. In fact, our
in vitro assays showed a higher basal proliferation rate
and a higher migration rate of U87MG cells than T98G
cells, as reported by others [12-14]. These results par-
tially explain the tumorigenic ability of U87MG cells and
the absence of such ability in T98G cells.
In the present study, the proteomic approach used to
compare these two cell lines disclosed a differential pro-
tein profile that further corroborates the functional dif-
ferences between them. GRP78 protein expression was
four times higher in T98G cells than in U87MG cells.
Previous studies on fibroblast cells have shown that
thapsigargin and tunicamycin induce UPR and the most
significant temporal changes were observed for the
78 kDa glucose-regulated protein (GRP78) [15]. We used
Figure 1 Representative two-dimensional gel electrophoresis (2-DE) and relative protein abundance plotting of T98G and U87MG cell
lines. A) Protein extracts (300 μg) were applied to 7 cm IPG strips, pH 3-10 non-linear coupled to 12% polyacrylamide gels. Gels were stained
using colloidal Coomassie blue. B) Differential protein abundance was obtained by normalized spot volumes (% Vol.) and protein identification is
reported in Table 1.
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Table 1 Protein identification by MALDI-TOF/TOF-MS of tryptic peptides obtained from 2-DE spots of T98G and U87MG
glioma cell lines
Spot
ID
U87MG /
T98G
Expression
ratio ± c.v.
T98G /
U87MG
Expression
ratio ± c.v.
Anova
(p value)
Accession
number
(MW / pI)
Protein name CID - MS/MS
Prot
score
%
seq cov
Unique
peptides
Peptide sequence
1 1.34 ± 0.09 - 0.0053 UBIQ_HUMAN
(8565/6.56)
Ubiquitin 302 61.8 1040.24 34EGIPPDQQR42
1068.35 64ESTLHLVLR72
1082.37 55TLSDYNIQK63
1525.84 30IQDKEGIPPDQQR42
2 1.92 ± 0.34 - 0.0422 S10AA_HUMAN
(17259/9.59)
Protein S100-A10 58 10.3 1208.80 38EFPGFLENQK47
3 1.95 ± 0.52 - 0.0304 SSBP_HUMAN
(17259/9.59)
Single-stranded DNA-binding
protein, Mitochondrial
263 21.6 986.26 96DVAYQYVK103
1150.37 114IDYGEYMDK122
1613.00 67SGDSEVYQLGDVSQK81
4 1.87 ± 0.40 - 0.0356 PTMS_HUMAN
(11530/4.14)
Parathymosin 67 10.8 1076.33 5SVEAAAELSAK15
5 1.37 ± 0.18 - 0.0474 TEBP_HUMAN
(18982 / 4.35)
Prostaglandin E synthase 3 230 18.8 922.18 72SILCCLR78
1004.22 80GESGQSWPR88
1132.42 79KGESGQSWPR88
1446.70 36LTFSCLGGSDNFK48
6 1.39 ± 0.19 - 0.0454 TPIS_HUMAN
(26954 / 6.45)
Triosephosphate isomerase 530 34.5 955.17 7FVGGNWK14
1138.43 60IAVAAQNCYK69
1235.51 195SNVSDAVAQSTR206
1327.64 207IIYGGSVTGATCK219
1467.77 176TATPQQAQEVHEK188
1587.88 86DCGATWVVLGHSER99
1639.98 70VTNGAFTGEISPGMIK85
7 2.40 ± 0.52 - 0.0351 TPM4_HUMAN
(28636 / 4.67)
Tropomyosin alpha-4 chain 253 17.7 1015.23 45AEGDVAALNR54
1171.50 133LVILEGELER142
1244.53 56IQLVEEELDR65
1615.87 14IQALQQQADEAEDR27
8 3.26 ± 0.47 - 0.0023 1433E_HUMAN
(29345 / 4.63)
14-3-3 protein epsilon 519 28.2 908.21 43NLLSVAYK50
1206.57 216DSTLIMQLLR225
1238.60 107HLIPAANTGESK118
1257.58 131YLAEFATGNDR141
1385.78 131YLAEFATGNDRK142
1448.74 30VAGMDVELTVEER42
1837.36 154AASDIAMTELPPTHPIR170
9 1.57 ± 0.32 - 0.0458 LDHB_HUMAN
(36923 / 5.71)
L-lactate dehydrogenase B
chain
372 16.8 914.25 92IVVVTAGVR100
960.27 300GLTSVINQK308
1177.46 320SADTLWDIQK329
1249.48 159VIGSGCNLDSAR170
1696.03 8LIAPVAEEEATVPNNK23
10 2.19 ± 0.40 - 0.0330 ANXA1_HUMAN
(38942 / 6.57)
Annexin A1 381 13.3 909.05 205ALYEAGER212
1214.35 167DITSDTSGDFR177
1263.42 114TPAQFDADELR124
1740.87 189SEDFGVNEDLADSDAR204
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Table 1 Protein identification by MALDI-TOF/TOF-MS of tryptic peptides obtained from 2-DE spots of T98G and U87MG
glioma cell lines (Continued)
11 3.01 ± 1.08 - 0.0189 RINI_HUMAN
(51799 / 4.71)
Ribonuclease inhibitor 579 18.7 1150.41 35LDDCGLTEAR44
1161.46 196DSPCQLEALK205
1210.51 54VNPALAELNLR64
1347.66 342FLLELQISNNR352
1514.91 360ELCQGLGQPGSVLR373
1531.76 288ELSLAGNELGDEGAR302
1631.88 174ELTVSNNDINEAGVR188
12 1.51 ± 0.17 - 0.0388 STMN1_HUMAN
(17302 / 5.76)
Stathmin 219 29.5 1075.39 44DLSLEEIQK52
1166.46 86AIEENNNFSK95
1327.75 30ESVPEFPLSPPK41
1389.81 15ASGQAFELILSPR27
13 2.99 ± 1.16 - 0.0194 PRDX6_HUMAN
(25149 / 6.0)
Peroxiredoxin-6 354 22.8 907.12 156NFDEILR162
916.19 175VATPVDWK182
1192.53 145LSILYPATTGR155
1396.66 42DFTPVCTTELGR53
1583.75 85DINAYNCEEPTEK97
14 1.39 ± 0.14 - 0.0311 PDIA3_HUMAN
(57181 / 5.98)
Protein disulfide-isomerase A3 449 15.8 996.28 131QAGPASVPLR140
1085.33 95YGVSGYPTLK104
1173.40 336FVMQEEFSR344
1192.44 63LAPEYEAAATR73
1237.40 108DGEEAGAYDGPR119
1369.62 367SEPIPESNDGPVK379
1681.91 434MDATANDVPSPYEVR448
15 - 2.33 ± 0.51 0.0099 MIF_HUMAN
(12647 / 7.74)
Macrophage migration
inhibitory factor
79 17.4 1045.37 79LLCGLLAER87
1304.69 2PMFIVNTNVPR12
16 - 1.83 ± 0.28 0.0070 PPIA_HUMAN
(18240 / 7.68)
Peptidyl-prolyl cis-trans
isomerase A
337 32.7 1056.15 20VSFELFADK28
1155.24 83FEDENFILK91
1248.37 155KITIADCGQLE165
1295.21 134EGMNIVEAMER144
1615.52 56IIPGFMCQGGDFTR69
17 - 3.62 ± 0.65 0.0022 PRDX1_HUMAN
(22338 / 8.27)
Peroxiredoxin-1 178 19.6 921.18 129GLFIIDDK136
1108.45 111TIAQDYGVLK120
1197.56 159LVQAFQFTDK168
1212.59 141QITVNDLPVGR151
18 - 2.30 ± 0.31 0.0009 EF1D_HUMAN
(31236 / 4.9)
Elongation factor 1-delta 458 24.6 974.13 233LVPVGYGIR241
1088.16 39QENGASVILR48
1359.47 84IASLEVENQSLR95
1528.59 25FYEQMNGPVAGASR38
19 - 2.10 ± 0.60 0.0214 HNRPC_HUMAN
(33727 / 4.95)
Heterogeneous
nuclearribonucleoproteins C1/
C2
123 8.8 904.11 136MYSYPAR142
944.28 143VPPPPPIAR151
1330.71 51GFAFVQYVNER61
20 - 1.87 ± 0.47 0.0476 SET_HUMAN
(33488 / 4.23)
Protein SET 290 11.7 1209.45 123VEVTEFEDIK132
1274.57 58LNEQASEEILK68
1447.63 155EFHLNESGDPSSK167
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thapsigargin to induce UPR and the agent caused an in-
crease of GRP78 expression in both cell lines and a
significant decrease in cell migration. Interestingly,
migration reduction was much more evident in U87MG
than in T98G cells. These results suggest that GRP78 and
other proteins altered by the action of thapsigargin as a
result of UPR participate in a negative loop for cell
migration, and the lower expression of GRP78 in U87MG
cells may contribute to the tumorigenic ability of these
cells. This observation clearly requires further investiga-
tion focusing on GRP78 knockdown by RNA of interfe-
rence. In agreement with our data, GRP78 silencing
increased cell migration in both HepJ5 and Mahlavu
cells and overexpressed GRP78 suppressed the migra-
tory ability of skHep1 cells and this effect on GRP78-
mediated cell migration was attributed to an increased
vimentin expression in hepatocellular carcinoma cells
[16,17]. In human brain tumors, we observed that the
GRP78 expression at the mRNA and protein level showed
a scattered pattern in grade IV astrocytomas, as opposed
to a grouped pattern in grade I astrocytomas and in non-
neoplastic tissue. This result suggests an important
participation of GRP78 in the already well-known he-
terogeneity of astrocytomas which perhaps could be useful
as a prognostic factor.
Metabolic reprogramming is an additional relevant aspect
of malignant cells [18]. Activation of the glycolytic pathway
even under aerobic conditions (Warburg effect) assures
tumor growth, migration and invasion [19]. Cumulative
reports have shown that GBM cells are able to increase cell
migration and invasion despite the irregular blood supply
in a hypoxic microenvironment by activating glycolysis
Table 1 Protein identification by MALDI-TOF/TOF-MS of tryptic peptides obtained from 2-DE spots of T98G and U87MG
glioma cell lines (Continued)
21 - 3.87 ± 1.03 0.0340 G6PD_HUMAN
(59712 / 6.39)
Glucose-6-phosphate1-
dehydrogenase
516 15.7 947.20 10TQVCGILR17
1003.28 220IFGPIWNR227
1059.38 167IIVEKPFGR175
1133.39 321GYLDDPTVPR330
1174.51 183LSNHISSLFR192
1192.42 499VGFQYEGTYK508
1233.58 206EMVQNLMVLR215
1809.05 105NSYVAGQYDDAASYQR120
22 - 3.20 ± 1.20 0.0491 TBA1A_HUMAN
(50820 / 4.94)
Tubulin alpha-1A chain 390 14.9 904.06 395FDLMYAK401
1016.30 327DVNAAIATIK336
1086.36 113EIIDLVLDR121
1250.36 312YMACCLLYR320
1719.98 216NLDIERPTYTNLNR229
1826.21 353VGINYQPPTVVPGGDLAK310
23 - 3.73 ± 1.52 0.0338 GRP78_HUMAN
(72446 / 5.07)
78 kDa glucose-regulated
protein
830 20.5 987.10 533LTPEEIER540
1192.36 465VYEGERPLTK474
1212.32 377EFFNGKEPSR386
1218.36 186DAGTIAGLNVMR197
1229.35 50VEIIANDQGNR60
1317.44 563NELESYAYSLK573
1431.53 102TWNDPSVQQDIK113
1461.64 354SDIDEIVLVGGSTR367
1567.70 61ITPSYVAFTPEGER74
1678.79 82NQLTSNPENTVFDAK96
1838.01 448SQIFSTASDNQPTVTIK464
24 - 1.69 ± 0.29 0.0224 GRP75_HUMAN
(73965 / 5.87)
Stress-70 protein,
mitochondrial
545 11.5 1243.42 207DAGQISGLNVLR218
1291.49 395VQQTVQDLFGR405
1362.58 349AQFEGIVTDLIR360
1451.59 86TTPSVVAFTADGER99
1463.67 378SDIGEVILVGGMTR391
1695.86 188NAVITVPAYFNDSQR202
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[20,21]. It has also been shown that GBM cells present suf-
ficient glycolytic capacity to support the migration of tumor
cells without mitochondrial participation [22-24].
Interestingly, our proteomic data showed that U87MG
cells, with a higher migration rate than T98G cells, pre-
sented overexpression of several enzymes involved in
glycolysis, whereas T98G presented overexpression of
glucose-6-phosphate 1-dehydrogenase (G6PD), the en-
zyme that commands the shift of glycolysis to the pentose
phosphate pathway (PPP). It has been recently reported
that G6PD is under regulation of cytoplasmic p53 which
regulates its biosynthesis by direct inactivation of G6PD
[25,26]. Notably, G6PD overexpression was observed in
the T98G cell line presenting mutated TP53. Therefore, it
is reasonable to speculate that TP53 mutation in this cell
line decreases cytoplasmic p53, leading to less inactivation
of G6PD, and consequently to attenuated activation of gly-
colysis because of the shift to PPP. This metabolic repro-
gramming might ultimately interfere with the ability of
the T98G cell line to induce tumors in nude mice.
In summary, the present report provides the proteomic
profile of two glioma cell lines with distinct tumorigenic
potential, contributing to a better understanding of their
functional differences at the protein level and highlights
the involvement of GRP78 and proteins involved in UPR
in the migration of these two glioma cell lines.
Conclusions
Taken together, the present results suggest an important
role of proteins involved in key functions such as gly-
colysis and cell migration that may explain the difference
in tumorigenic ability between these two glioma cell
lines and may be extrapolated to the differential aggres-
siveness of glioma tumors.
Figure 2 Functional analysis of cell lineages and expression of
GRP78. A) The U87MG cell line shows a higher proliferation rate
than the T98G cell line. Cells were counted in a Neubauer chamber
at 24 h intervals; B) Thapsigargin decreased tumor cell migration. A
transwell migration assay was carried out in U87MG and T98G cells
after 18 h of incubation with or without 1 μM thapsigargin. Cells
that migrated to the low chamber were fixed, stained, and counted
as described in Materials and Methods. C) Thapsigargin increased
GRP78 expression. Western blot analysis with anti-GRP78 antibody
was carried out in both cell lines after 24 h of incubation with 1 μM
thapsigargin. Expression of β-actin in cell lysates was used as a control.
Figure 3 GRP78 expression in grade I and grade IV astrocytomas
(AGI and AGIV) relative to non-neoplastic (NN) brain tissues.
A) Tissues were reverse transcribed into cDNAs and then analyzed by
quantitative Real Time PCR (qRT-PCR) using the SYBR Green method.
The geometric mean of the three genes (HPRT, GUSB and TBP) was
used for relative expression analysis. The differences of relative GRP78
expression were statistically significant between groups, ***p=0.0001.
One-way ANOVA and Post hoc Tukey’s test was used to
calculate the differences of expression between groups
(***p<0.0001). *** p< 0.0001 (NN versus AGI and NN versus AGIV).
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Material and methods
Cell culture and tumor samples
GBM cell lines, T98G and U87MG, were maintained at
37°C in 5% CO2, in α-MEM medium supplemented with
15% heat-inactivated fetal bovine serum (FBS) and DMEM
medium supplemented with 10% FBS, respectively. Cells
were cultured up to 80% confluence and were harvested
after trypsin treatment. Cells were then washed twice in
PBS, pH 7.4, and counted in a Neubauer chamber. An ali-
quot of the cell pellet containing~1x107 cells was frozen
at -80°C for further protein extraction. For thapsigargin
treatment, cells were cultured in 35 mm plates with 1 μM
thapsigargin in medium for 24 h. The use of human ma-
terial in this study was approved by the National Bioethics
Commission of Brazil and by the Ethics Committee of the
Medical School of Sao Paulo, University of Sao Paulo.
Written consent was obtained from patients authorizing
the use of their tissues in the present investigation.
Cell proliferation and doubling time assay
Cells were counted in a Neubauer chamber. Briefly,
2 × 105 cells of each line were plated onto 100 mm2
plates. Every 24 h the cells were treated with trypsin,
centrifuged and resuspended in PBS for counting after
dilution in a Turkey’s solution. Two counts were per-
formed for each lineage, in triplicate. For doubling time
analysis, cells were plated onto 6-well plates in triplicate
at a concentration of 5 × 104 cells/well in DMEM. After
24, 48, 72 and 96 h, cells were collected after trypsiniza-
tion and counted in a Neubauer chamber. Doubling time
(in h) was calculated using the following formula = h× ln
(2)/ln(c2/c1), where c is the number of cells at each time
of collection and ln is a neperian logarithm. (Roth V,
2006 http://www.doubling-time.com/compute.php).
Cell migration assay
Transwell assays were done using 24-well plate inserts
with pores 8 μm in diameter (Greiner Bio-One), in
which 2.5 × 104 cells/mL (500μL/well) were plated on
the top of the insert in serum-free medium contain-
ing 1 μM thapsigargin. The bottom of the pit was
covered with 500 μL of DMEM and α-MEM with 10
or 15% fetal bovine serum (FBS), respectively, for the
U87MG and T98G cell lines. Cells were allowed to
migrate toward to the bottom chamber containing
medium with FBS for 18 h. The cells on the upper
membrane surface were removed with a cotton tip,
and the migratory cells attached to the lower mem-
brane surface were fixed in 4% paraformaldehyde and
stained with 0.2% crystal violet solution. The lower
membrane surface was photographed in ten randomly
selected fields under 100x microscope magnification
and the cells were counted in each field using the
Image J software (NIH, Bethesda, MD). The number
of migratory cells was obtained by triplicate analysis
of three individual wells.
Figure 4 Immunohistochemical detection of GRP78 in patient tumor samples. A) Non-neoplastic tissue, B) Anaplastic pilocytic astrocytoma
grade I, C) astrocytoma grade IV and D) Scattered graphics of GRP78 relative expression. All immunohistochemical figures are presented at 200x
magnification and the figure inserts at 400x magnification. All prepared slides were analyzed independently by two pathologists, and the positive
reaction was measured for GRP78 as the percentage of cytoplasm positive cells. Zero (0), when no positivity was detected; 1, when up to 25% of
positive cells were present; 2, for 26-50% of positive cells; 3, for 51-75% of positive cells, and 4, for over 76% of positive cells.
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Protein extraction
T98G and U87MG cell pellets of were thawed at 4°C and
resuspended in lysis solution with 7.7 M urea, 2.2 M thio-
urea, 4% CHAPS and a protease inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO), submitted to three cycles of
5 minutes in an ultrasound bath (UltraSonic Clear 750,
UNIQUE) for complete pellet resuspension and centri-
fuged at 20,000 x g for 30 min at 4°C. Protein concentra-
tion was determined by the method of Bradford [27].
Two-dimensional gel electrophoresis
The first dimensional is electric focusing (IEF) was done
on the IPGphor system (Ettan IPGphor I GE Healthcare,
Psicataway, NJ) using Immobiline Dry IPG strips (7 cm,
pH 3-10 non-linear; GE Healthcare, Uppsala, Sweden)
and 300 μg of protein extract were applied to IPG strips.
IEF was started at 500 V and the voltage was gradually
increased to 5000 V until completing 40,000 volt-h and
the procedure ended at 8000 V for 30 minutes. After IEF,
the gel strips were equilibrated in buffer I for reduction
(6 M urea; 50 mM Tris–HCl, pH 8.8, 2% SDS, 30%
glycerol, and 1% DTT), and buffer II for alkylation (1%
DTT was replaced with 2.5% iodoacetamide); each sample
was gently shaken for 15 minutes at room temperature
(22°C). The second dimensional separation was done on
12.5% SDS-polyacrylamide gels (10 cm×10 cm×1 mm)
using Hoofer SE 600 vertical chambers. Gels were stained
with colloidal Comassie blue-G250 and images were
captured by transmission scanning (Image Scanner,
Pharmacia-Biotech, Sweden) using Magic Scan software
(GE-Healthcare). Gel images were analyzed with the Image
Master software, v.7.0 (GE-Healthcare). Replicates of 12
gels (triplicate of gels for each cell line) were obtained, and
statistical analysis was carried out using Anova followed by
the Student’s t-test for the selection of protein spots
(Additional file 2: Table S2).
Trypsin digestion and mass spectrometry analysis
Selected protein spots were manually excised from the gels.
SDS and Coomassie blue were removed by successive
changes of 50% acetonitrile in 0.1 M of ammonium bicar-
bonate, pH 7.8, following dehydration in neat acetonitrile
and drying in Speed Vac (Savant, New York, NY, USA).
Proteins were then digested with 0.5 μg of modified trypsin
(Promega Corp., Madison, WI, USA) in 0.1 M ammonium
bicarbonate for 18 h at 37°C. The reaction was stopped by
the addition of 1 μL of neat formic acid. Tryptic peptides
were extracted by passive elution and desalted in micro-
tips filled with reverse-phase resin (POROS R2, Perceptive
Biosystems, Foster City, CA, USA), previously equilibrated
in 0.2% formic acid. The sample was desalted by two
washes of 150 μL of 0.2% formic acid. Peptides were
eluted in 30 μL of 60% methanol/5% formic acid solution,
concentrated in Speed Vac and resuspended in α-cyano-4-
hydroxycinnamic acid matrix solution (5 mg/mL). Two to
five micro liters of each sample were loaded in MALDI
target and analyzed with a MALDI-TOF-TOF mass
spectrometer (Axima Performance – Kratos-Shimadzu,
Manchester, UK).
Protein identification
PMF and CID-MS/MS spectra from 2 DE selected protein
spots were submitted to protein identification by search-
ing against the Swiss-Prot database version 57.2 filtered
for Homo sapiens (total of 20,402 human sequences) using
MASCOT version 2.2.04. The database search parameters
were as follows: trypsin hydrolysis, one missing cleavage
was allowed, fixed modification for carbamidomethyl-Cys
and variable modification for methionine oxidation. The
mass tolerance for precursor ions was 1.2 Da and mass
Figure 5 Quantification of glucose and lactate in T98G and
U87MG cell lines under normoxic culture conditions.
A) Quantification of glucose in μg/cell (mean±SD, n = 6, 24 h,
p = 0.621 and 48 h, p = 0.0645, Student’s t-test). B) Quantification of
lactate in μg/cell (mean±SD, n = 6, 24 h, p = 0.001 and 48 h
p= 0.0005, Student’s t test).
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tolerance for fragment ions was set at 0.8 Da. Protein
identification was supported by MS/MS analysis of indi-
vidual ions using CID-MS/MS. Proteins were identified on
the basis of at least two unique peptides or one peptide if
its score was higher than 35 (p < 0.05) or the amino acid
sequence was consistently covered by a series of b and y
type ion fragments (Additional file 2: Table S2 and pride
XML compatible file as Additional file 3).
Protein ontology
The differentially expressed proteins were submitted to
GO:: Term Finder software [28] and functional classifi-
cation for biological processes was performed by gene
ontology (Additional file 1).
Western blot
Western blotting was used to verify the expression of
GRP78 in the protein extract from U87MG and T98G
cell lines before and after thapsigargin. Samples were
submitted to SDS-PAGE (12% polyacrylamide gels) and
transferred to Hybond PVDF membranes (Amersham
Biosciences) for one h at 35 V. A PVDF membrane was
blocked with 5% dry non-fat milk, followed by incuba-
tion with goat polyclonal anti-GRP78 antibody (Santa
Cruz Biotechnology). After TBS-T washing, PVDF mem-
branes were incubated with donkey anti-goat immuno-
globulin-peroxidase conjugate (Sigma Chemical) for 1 h
at room temperature (22°C). The immune complexes
were visualized by enhanced chemiluminescence using
an ECL kit (GE Healthcare), and detected using Image
Quant LAS 4000 mini (GE-Healthcare, USA).
Quantification of glucose and lactate under normoxic cell
culture conditions
U87MG and T98G cell lines were seeded onto six well
plates and incubated for 24 and 48 h with 3.5 × 104 cells
(10 cm2/well) containing 2 mL of culture medium (4 g/L
glucose, 2.6 g/L HEPES, 3.6 g/L NaHCO3, 1% penicillin/
streptomycin, 1% L-glutamine, 10% FBS). In order to
measure glucose consumption and lactate formation by
U87MG and T98G cells, 3.5 × 104 cells were incubated
in six-well plates. After a stabilization period, the plates
were washed using phosphate buffered saline (PBS) and
the medium was replaced with 2 mL of phenol-red-free
minimum medium containing glucose, fetal calf serum
(FCS) and L-glutamine. The assays were performed 24 and
48 h after incubation, along with cell counting. For glucose
and lactate quantification, 200 μL supernatant samples
were collected in micro tubes and frozen until the time for
assay. Glucose quantification was performed using an en-
zymatic colorimetric assay based on the D-glucose oxidase
method (Latest Diagnostic, São Paulo, Brazil). The color in-
tensity was measured at 520 nm. The D-Lactate Assay Kit
(Latest Diagnostic, São Paulo, Brazil) was used to measure
D-lactate which is specifically oxidized by D-lactate oxidase
and generates proportional color (λmax=550 nm). The
protocols were developed according to manufacturer
instructions. Data were reported as glucose and lactate in
μg/cell and represent the mean ± SEM of 6 determinations,
and were analyzed by the Student’s t test.
Total RNA extraction and cDNA synthesis
Total RNA was extracted from tissues using RNeasy
Mini Kit (Qiagen Inc, Hilden, Germany). RNA quantifi-
cation and purification was evaluated by measuring ab-
sorbance and A260/A280 ratios in the range of 1.8-2.0
were considered satisfactory for purity standards. De-
naturing agarose gel electrophoresis was used to assess
the quality of the samples. Synthesis of cDNA was per-
formed by reverse transcription from 1 μg total RNA,
previously treated with 1 unit of DNase I (FPLC-pure,
GE Healthcare, Piscataway, NJ) using random and oligo
(dT) primers, an RNase inhibitor and Superscript III
(Invitrogen Inc, Carlsbad, CA), following the manufac-
turer’s recommendations. The resulting cDNA was then
treated with 1 unit of RNase H (GE Healthcare), diluted
with TE buffer, and stored at -20°C until later use.
Quantitative real time (qRT-PCR)
The expression level of GRP78 was determined by qRT-
PCR using the SYBR Green approach, in duplicate. Quan-
titative data were normalized relative to the internal
housekeeping genes hypoxanthine phosphoribosyltransfer-
ase 1 (HPRT), beta-glucuronidase (GUSB) and TATA-box
binding protein (TBP). The geometric mean of the three
genes was used for relative expression analysis. Primer
sequences were as follows (5′-3′): GRP78 F: GGT
GACCTGGTACTGCTTGATGT, GRP78 R: TCCTTGG
AATCAGTTTGGTCAT, HPRT F: TGAGGATTTGGA
AAGGGTGT, HPRT R: GAGCACACAGAGGGCTAC
AA, GUSB F: AAAATACGTGGTTGGAGAGCTCATT,
GUSB R: CCGAGTGAAGATCCCCTTTTTA, TBP F:
AGGATAAGAGAGCCACGAACCA and TBP R: CTT
GCTGCCAGTCTGGACTGT synthesized by IDT (Inte-
grated DNA Technologies, Coralville, IA). Sybr Green I
amplification mixtures (12 μl) contained 3 μl of cDNA, 6 μl
of 2x Power Sybr Green I Master Mix (Applied Bios stems,
Foster City, CA), and forward and reverse primers. Reac-
tions were run on an ABI 7500 Real-Time PCR System
(Applied Bios stems). The cycle conditions comprised incu-
bation at 50°C for 2 min to activate UNG, initial denatur-
ation at 95°C for 10 min, and 40 cycles at 95°C for 15 sec,
and 60°C for 1 min. The minimum concentration of pri-
mers was determined by the lowest threshold cycle (Ct)
and maximum amplification efficiency while minimizing
nonspecific amplification (at a final concentration of 200
nM for GRP78, HPRT and TBP, and of 400 nM for GUSB).
Analysis of DNA melting curves demonstrated a single
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peak for the whole set of primers. Standard curves were
analyzed for all genes to check the efficiency of amplifica-
tion of each gene. Additionally, agarose gel electrophoresis
was employed to check the size of the amplified PCR pro-
duct. GRP78 relative expression levels were analyzed in 10
non-neoplastic brain tissues (NN), 10 grade I astrocytomas
(AGI) and 20 grade IV astrocytomas (AGIV). The 2-ΔΔCT
equation was applied to calculate the relative expression of
tumor samples versus the mean of non-neoplastic tissues
where ΔCt = mean Ct GRP78 – Ct geometric mean of
housekeeping genes and ΔΔCt = ΔCt tumor – mean ΔCt
non-neoplastic tissues [29].
Immunohistochemistry
For immunohistochemical detection of GRP78, tissue sec-
tions were routinely processed and subjected to antigen re-
trieval. Briefly, slides were immersed in 10 mM citrate
buffer, pH 6.0 and incubated at 122°C for 3 min using an
electric pressure cooker (BioCare Medical Walnut Creek,
CA). Specimens were then blocked and further incubated
with a mouse monoclonal antibody raised against human
GRP78 (goat polyclonal, N-20, Santa Cruz – sc-1050) at a
final dilution of 1:200 at 16-20°C for 16 h. The reaction was
developed using a Novolink commercial kit (Novocastra,
New Castle, UK) at room temperature using diaminoben-
zidine, and Harris hematoxylin for nuclear staining. All
prepared slides were independently analyzed by two
pathologists, and the positive reaction was quantitated for
GRP78 as the percentage of positive cytoplasm cells: zero
(0), when no positivity was detected; 1, when up to 25% of
positive cells were present; 2, for 26-50% of positive cells;
3, for 51-75% of positive cells, and 4, for over 76% of posi-
tive cells.
Statistical analysis
The statistical analysis of GRP78 expression by qRT-PCR
in AGI, AGIV samples and NN tissues was performed
by one-way ANOVA. Post hoc Tukey’s tests were applied
to compare the differences between the non-neoplastic
group and each tumor group Differences were consi-
dered to be statistically significant at p < 0.05.
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